The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.

@article{Banelli2015TheHD,
  title={The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.},
  author={Barbara Banelli and Elisa Carra and Federica Barbieri and Roberto W{\"u}rth and Federica Parodi and Alessandra Pattarozzi and Roberta Carosio and Alessandra Forlani and Giorgio Allemanni and Daniela Marubbi and Tullio Florio and Antonio Daga and Massimo Romani},
  journal={Cell cycle},
  year={2015},
  volume={14 21},
  pages={3418-29}
}
Notwithstanding current multimodal treatment, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), median survival of glioblastoma (GBM) patients is about 14 months, due to the rapid emergence of cell clones resistant to treatment. Therefore, understanding the mechanisms underlying chemoresistance is mandatory to improve treatments' outcome. We generated TMZ resistant cells (TMZ-R) from a GBM cell line and from cancer stem cell-enriched cultures isolated from human GBMs. We… CONTINUE READING
Highly Cited
This paper has 65 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS
14 Citations
56 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

66 Citations

0204060201620172018
Citations per Year
Semantic Scholar estimates that this publication has 66 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 56 references

Similar Papers

Loading similar papers…